Gilead Sciences, Inc. (GILD) Stake Lifted by Vicus Capital

Vicus Capital grew its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 4.5% in the first quarter, HoldingsChannel reports. The firm owned 8,220 shares of the biopharmaceutical company’s stock after purchasing an additional 351 shares during the period. Vicus Capital’s holdings in Gilead Sciences were worth $534,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Cornerstone Advisors Inc. lifted its stake in shares of Gilead Sciences by 17.3% in the first quarter. Cornerstone Advisors Inc. now owns 3,713 shares of the biopharmaceutical company’s stock worth $241,000 after buying an additional 548 shares in the last quarter. Alpha Omega Wealth Management LLC lifted its stake in shares of Gilead Sciences by 73.2% in the first quarter. Alpha Omega Wealth Management LLC now owns 48,688 shares of the biopharmaceutical company’s stock worth $3,165,000 after buying an additional 20,576 shares in the last quarter. Wedge Capital Management L L P NC lifted its stake in shares of Gilead Sciences by 21.9% in the first quarter. Wedge Capital Management L L P NC now owns 603,969 shares of the biopharmaceutical company’s stock worth $39,264,000 after buying an additional 108,525 shares in the last quarter. Crossmark Global Holdings Inc. lifted its stake in shares of Gilead Sciences by 2.9% in the first quarter. Crossmark Global Holdings Inc. now owns 218,583 shares of the biopharmaceutical company’s stock worth $14,210,000 after buying an additional 6,174 shares in the last quarter. Finally, Lenox Wealth Management Inc. lifted its stake in shares of Gilead Sciences by 1.8% in the first quarter. Lenox Wealth Management Inc. now owns 9,059 shares of the biopharmaceutical company’s stock worth $589,000 after buying an additional 156 shares in the last quarter. Hedge funds and other institutional investors own 79.94% of the company’s stock.

Several research analysts have recently issued reports on the stock. Mizuho set a $88.00 target price on shares of Gilead Sciences and gave the stock a “buy” rating in a research note on Friday. Evercore ISI reiterated a “buy” rating on shares of Gilead Sciences in a research note on Friday. JPMorgan Chase & Co. reiterated a “buy” rating and issued a $87.00 target price on shares of Gilead Sciences in a research note on Tuesday, May 7th. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research note on Monday, May 6th. Finally, Raymond James set a $83.00 target price on shares of Gilead Sciences and gave the stock a “buy” rating in a research note on Friday, May 3rd. Nine analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. Gilead Sciences has an average rating of “Buy” and a consensus target price of $81.61.

In related news, Director Richard James Whitley sold 9,534 shares of the stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $65.48, for a total transaction of $624,286.32. Following the transaction, the director now owns 34,669 shares in the company, valued at $2,270,126.12. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director John Francis Cogan sold 2,700 shares of the stock in a transaction that occurred on Wednesday, March 20th. The shares were sold at an average price of $65.07, for a total transaction of $175,689.00. Following the transaction, the director now owns 57,560 shares in the company, valued at approximately $3,745,429.20. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 47,670 shares of company stock worth $3,142,526. 0.20% of the stock is owned by insiders.

Shares of Gilead Sciences stock opened at $66.36 on Friday. The company has a market cap of $84.60 billion, a P/E ratio of 10.79, a P/E/G ratio of 0.81 and a beta of 1.14. Gilead Sciences, Inc. has a twelve month low of $60.32 and a twelve month high of $79.61. The company has a debt-to-equity ratio of 1.09, a quick ratio of 3.53 and a current ratio of 3.62.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported $1.76 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.53 by $0.23. The company had revenue of $5.28 billion for the quarter, compared to the consensus estimate of $5.29 billion. Gilead Sciences had a net margin of 26.40% and a return on equity of 37.98%. The firm’s revenue for the quarter was up 3.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.48 earnings per share. On average, research analysts anticipate that Gilead Sciences, Inc. will post 6.6 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 27th. Investors of record on Friday, June 14th will be given a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, June 13th. This represents a $2.52 dividend on an annualized basis and a yield of 3.80%. Gilead Sciences’s dividend payout ratio (DPR) is 40.98%.

TRADEMARK VIOLATION NOTICE: “Gilead Sciences, Inc. (GILD) Stake Lifted by Vicus Capital” was first published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://www.baseballdailydigest.com/news/2019/05/19/gilead-sciences-inc-gild-stake-lifted-by-vicus-capital.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Its primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

Recommended Story: Why does a company issue an IPO?

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.